Skip to content
Biodatica
Start free

EyePoint Pharmaceuticals, Inc.

Gilbert, Arizona

Phase III
Sign in to watch

What changed

Phase III trial registered: CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

1w agoTrial registeredJul 6, 2026Source filing (opens the source filing in a new tab)

Momentum

71no change

Momentum 71 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Feb 9, 2026

    Diabetic Macular Edema, DME, Diabetic Macular Edema (DME) · RECRUITING · sponsor: EyePoint Pharmaceuticals, Inc. · CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

    ClinicalTrials.gov · NCT07449923 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources